Comparison of Abiraterone Acetate Versus Ketoconazolein Patients with Metastatic Castration Resistant Prostate Cancer Refractory to Docetaxel

BACKGROUND: Abiraterone, a potent CYP 17 inhibitor, is standard treatment in docetaxel refractory, metastatic castrate resistant prostate cancer (mCRPC). However, in countries where abiraterone has not been approved yet, or for patients who cannot afford it, ketoconazole is used as an alternative CY...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Prostate
Huvudupphovsmän: Peer, Avivit, Gottfried, Maya, Sinibaldi, Victoria, Carducci, Michael A., Eisenberger, Mario A., Sella, Avishay, Leibowitz-Amit, Raya, Berger, Raanan, Keizman, Daniel
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4696030/
https://ncbi.nlm.nih.gov/pubmed/24338986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22765
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk